Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Infection and Drug Resistance|May 8, 2018
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA ProjectPaola Bagella, Giuseppe Vl De Socio, Elena Ricci, et al.
Viruses|March 30, 2023
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life StudyAndrea De Vito, Elena Ricci, Barbara Menzaghi, et al.
BMC Infectious Diseases|April 14, 2023
Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimensPaolo Maggi, Elena Delfina Ricci, Stefania Cicalini, et al.
AIDS (London, England)|March 17, 2023
Incident diabetes in course of antiretroviral therapyLucia Taramasso, Nicola Squillace, Elena Ricci, et al.
Plos One|August 9, 2023
Real-life safety of Emtricitabine/Tenofovir Alafenamide/BictegravirNicola Squillace, Elena Ricci, Paolo Maggi, et al.
Journal of Clinical Medicine|August 27, 2021
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in ItalyAlessandro Maria Vannucchi, Andrea Mortara, Andrea D'Alessio, et al.
BMC Infectious Diseases|September 23, 2022
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?Paolo Maggi, Giuseppe Vittorio De Socio, Barbara Menzaghi, et al.
Open Forum Infectious Diseases|June 25, 2020
Factors Associated With Weight Gain in People Treated With DolutegravirLucia Taramasso, Paolo Bonfanti, Elena Ricci, et al.
AIDS Patient Care and Stds|September 15, 2021
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Andrea De Vito, Elena Delfina Ricci, et al.
Pageof 10